Cartesian Therapeutics, Inc. (RNAC) Operating cash flow 2016–2025
Cartesian Therapeutics, Inc. (RNAC) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$73.9MFY2025 · since FY2016: -$19.8M → -$73.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$73.9M | -212.3% |
| FY2024 | -$23.7M | +53.7% |
| FY2023 | -$51.2M | -61.7% |
| FY2022 | -$31.6M | +47.6% |
| FY2021 | -$60.4M | -273.1% |
| FY2020 | $34.9M | +167.8% |
| FY2019 | -$51.4M | +13.1% |
| FY2018 | -$59.2M | -13.7% |
| FY2017 | -$52.0M | -163.3% |
| FY2016 | -$19.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RNAC financial trends
RNAC RevenueRNAC Net incomeRNAC Net marginRNAC Gross profitRNAC Gross marginRNAC Operating incomeRNAC Operating marginRNAC Free cash flowRNAC Capital expendituresRNAC Return on equityRNAC Stock buybacksRNAC Dividends paidRNAC Total assetsRNAC Total liabilitiesRNAC Shareholders’ equityRNAC overview →